Materiały źródłowe

• #1 Polymyositis and dermatomyositis epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Polymyositis_and_dermatomyositis_epidemiology_and_demographics

  The incidence of polymyositis and dermatomyositis is approximately 1-5 per 100,000 individuals worldwide. The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide. […] The incidence of polymyositis and dermatomyositis is approximately 2 per 100,000 individuals worldwide. […] In 2010, the incidence of polymyositis and dermatomyositis was estimated to be 1-1.3 cases per 100,000 individuals in Japan annually. […] The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide. […] In 2003, the prevalence of polymyositis and dermatomyositis was estimated to be 21.5 cases per 100,000 individuals in Quebec. […] In 2010, the prevalence of polymyositis and dermatomyositis was estimated to be 13.2 cases per 100,000 individuals in Japan.

• #2 Autoimmune Myopathies – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK532860/

  The estimated prevalence of polymyositis and dermatomyositis (PM/DM) is 5 to 22 per 100,000 persons, and the incidence is approximately 1.2 to 19 per million persons at risk per year. […] The incidence of myositis is increasing over time due to an increase in the detection rate. […] Dermatomyositis is bimodal in age distribution, with one peak at 5 to 15 years and another at 45 to 60 years. Polymyositis rarely occurs in the pediatric age group, and the mean age is between 50 and 60 years. […] The overall female-to-male incidence ratio is 2 to 3:1. In the United States, the Black race to White race ratio of incidence is 3 to 4:1. […] In Europe, the prevalence significantly increases from the north to the south, and this may be due to either environmental or genetic reasons.

• #3 Polymyositis | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/27417

  Autoimmune disorders are the leading cause of increased mortality among the middle-aged population in the United States, with varying incidence rates. Polymyositis rarely presents in childhood and usually affects people 20 and older. Dermatomyositis, however, has a bimodal age distribution affecting the population between 5 to 15 years and 45 to 60 years. The chances of disease development are almost double in women than in men, which is exactly the opposite of IBM. In the United States population, the rate of development of this autoimmune disorder is about 0.5 to 8.4 cases per 100,000 individuals. Having ethnic variation, it has been more commonly reported in Black populations than in White.

• #4 Polymyositis: Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/335925-overview

  Idiopathic inflammatory myopathies are relatively rare diseases, with an incidence in the United States that ranges from 0.5-8.4 cases per million population. Polymyositis is more common in the United States within the Black population, with the estimated Black-to-White incidences for polymyositis and dermatomyositis being 5:1 and 3:1, respectively. Internationally, polymyositis is less common among the Japanese. […] Polymyositis and dermatomyositis are more common in women than in men (2:1 ratio), while inclusion body myositis is twice as common in men. […] Polymyositis usually affects adults older than 20 years, especially those aged 45-60 years. Polymyositis rarely affects children. The age of onset of polymyositis with another collagen vascular disease is related to the associated condition. […] Five-year survival rates in polymyositis have been estimated at more than 80%. Mortality is most often related to associated malignancy or pulmonary complications; elderly patients with cardiac involvement or dysphagia also have a higher mortality rate.

• #5 Myositis – Polymyositis and Dermatomyositis – Patient.info

  https://patient.info/doctor/myositis-polymyositis-and-dermatomyositis

  Few epidemiological studies have been published. […] One US study showed the incidence and prevalence of dermatomyositis to be 1.4 and 5.8 cases per 100,000 people respectively, with female preponderance and a higher prevalence among older age groups. […] For polymyositis, the incidence was 3.8 and the prevalence 9.7 per 100,000 people. However, polymyositis may have been over-diagnosed because not all studies were based on diagnostic muscle biopsies.

• #6 Polymyositis and dermatomyositis epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Polymyositis_and_dermatomyositis_epidemiology_and_demographics

  The incidence of polymyositis and dermatomyositis is approximately 1-5 per 100,000 individuals worldwide. The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide. […] The incidence of polymyositis and dermatomyositis is approximately 2 per 100,000 individuals worldwide. […] In 2010, the incidence of polymyositis and dermatomyositis was estimated to be 1-1.3 cases per 100,000 individuals in Japan annually. […] The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide. […] In 2003, the prevalence of polymyositis and dermatomyositis was estimated to be 21.5 cases per 100,000 individuals in Quebec. […] In 2010, the prevalence of polymyositis and dermatomyositis was estimated to be 13.2 cases per 100,000 individuals in Japan.

• #7 Autoimmune Myopathies – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK532860/

  The estimated prevalence of polymyositis and dermatomyositis (PM/DM) is 5 to 22 per 100,000 persons, and the incidence is approximately 1.2 to 19 per million persons at risk per year. […] The incidence of myositis is increasing over time due to an increase in the detection rate. […] Dermatomyositis is bimodal in age distribution, with one peak at 5 to 15 years and another at 45 to 60 years. Polymyositis rarely occurs in the pediatric age group, and the mean age is between 50 and 60 years. […] The overall female-to-male incidence ratio is 2 to 3:1. In the United States, the Black race to White race ratio of incidence is 3 to 4:1. […] In Europe, the prevalence significantly increases from the north to the south, and this may be due to either environmental or genetic reasons.

• #8 Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. | The Journal of Rheumatology

  https://www.jrheum.org/content/35/3/445

  OBJECTIVE: To determine the incidence and prevalence of sporadic inclusion body myositis (sIBM) and polymyositis (PM) in a population-based study. […] RESULTS: For sIBM, the age- and sex-adjusted incidence rates per 100,000 were 0.79 (95% confidence interval = 0.24-1.35), and for PM, 0.41 (95% CI 0.08-0.73). The age- and sex-adjusted prevalence rates per 100,000 were 7.06 (95% CI 0.87-13.24) for sIBM and 3.45 (95% CI 0.00-7.35) for PM. […] CONCLUSION: The incidence and prevalence rates for sIBM are higher than previously reported.

• #9 Polymyositis and dermatomyositis epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Polymyositis_and_dermatomyositis_epidemiology_and_demographics

  The incidence of polymyositis and dermatomyositis is approximately 1-5 per 100,000 individuals worldwide. The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide. […] The incidence of polymyositis and dermatomyositis is approximately 2 per 100,000 individuals worldwide. […] In 2010, the incidence of polymyositis and dermatomyositis was estimated to be 1-1.3 cases per 100,000 individuals in Japan annually. […] The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide. […] In 2003, the prevalence of polymyositis and dermatomyositis was estimated to be 21.5 cases per 100,000 individuals in Quebec. […] In 2010, the prevalence of polymyositis and dermatomyositis was estimated to be 13.2 cases per 100,000 individuals in Japan.

• #10 Polymyositis and dermatomyositis epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Polymyositis_and_dermatomyositis_epidemiology_and_demographics

  The incidence of polymyositis and dermatomyositis is approximately 1-5 per 100,000 individuals worldwide. The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide. […] The incidence of polymyositis and dermatomyositis is approximately 2 per 100,000 individuals worldwide. […] In 2010, the incidence of polymyositis and dermatomyositis was estimated to be 1-1.3 cases per 100,000 individuals in Japan annually. […] The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide. […] In 2003, the prevalence of polymyositis and dermatomyositis was estimated to be 21.5 cases per 100,000 individuals in Quebec. […] In 2010, the prevalence of polymyositis and dermatomyositis was estimated to be 13.2 cases per 100,000 individuals in Japan.

• #11 Incidence and prevalence of idiopathic inflammatory myopathies in Thailand from the Ministry of Public Health data analysis | Scientific Reports

  https://www.nature.com/articles/s41598-024-71633-7

  The epidemiology of idiopathic inflammatory myopathies (IIMs) varies by country. […] We aimed to assess the prevalence and incidence of IIM in the Thai population between 2017 and 2020. […] In 2017, the IIM cases numbered 9,074 among 65,204,797 Thais, resulting in a prevalence of 13.9 per 100,000 population (95% CI 13.6-14.2). […] IIMs were slightly more prevalent among women than men (16.8 vs 10.9 per 100,000). […] Between 2018 and 2020, the incidence of IIMs slightly declined from 5.09 (95% CI 4.9-5.27) in 2017 and 4.92 (95% CI 4.76-5.10) in 2019 to 4.43 (95% CI 4.27-4.60) per 100,000 person-years in 2020. […] The peak age group was 50-69 years. […] Between 2018 and 2020, the majority of cases occurred in southern Thailand, with incidence rates of 7.60, 8.34, and 8.74 per 100,000 person-years.

• #12 Autoimmune Myopathies – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK532860/

  The estimated prevalence of polymyositis and dermatomyositis (PM/DM) is 5 to 22 per 100,000 persons, and the incidence is approximately 1.2 to 19 per million persons at risk per year. […] The incidence of myositis is increasing over time due to an increase in the detection rate. […] Dermatomyositis is bimodal in age distribution, with one peak at 5 to 15 years and another at 45 to 60 years. Polymyositis rarely occurs in the pediatric age group, and the mean age is between 50 and 60 years. […] The overall female-to-male incidence ratio is 2 to 3:1. In the United States, the Black race to White race ratio of incidence is 3 to 4:1. […] In Europe, the prevalence significantly increases from the north to the south, and this may be due to either environmental or genetic reasons.

• #13 Polymyositis | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/27417

  Autoimmune disorders are the leading cause of increased mortality among the middle-aged population in the United States, with varying incidence rates. Polymyositis rarely presents in childhood and usually affects people 20 and older. Dermatomyositis, however, has a bimodal age distribution affecting the population between 5 to 15 years and 45 to 60 years. The chances of disease development are almost double in women than in men, which is exactly the opposite of IBM. In the United States population, the rate of development of this autoimmune disorder is about 0.5 to 8.4 cases per 100,000 individuals. Having ethnic variation, it has been more commonly reported in Black populations than in White.

• #14 Polymyositis | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/27417

  Autoimmune disorders are the leading cause of increased mortality among the middle-aged population in the United States, with varying incidence rates. Polymyositis rarely presents in childhood and usually affects people 20 and older. Dermatomyositis, however, has a bimodal age distribution affecting the population between 5 to 15 years and 45 to 60 years. The chances of disease development are almost double in women than in men, which is exactly the opposite of IBM. In the United States population, the rate of development of this autoimmune disorder is about 0.5 to 8.4 cases per 100,000 individuals. Having ethnic variation, it has been more commonly reported in Black populations than in White.

• #15 Autoimmune Myopathies – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK532860/

  The estimated prevalence of polymyositis and dermatomyositis (PM/DM) is 5 to 22 per 100,000 persons, and the incidence is approximately 1.2 to 19 per million persons at risk per year. […] The incidence of myositis is increasing over time due to an increase in the detection rate. […] Dermatomyositis is bimodal in age distribution, with one peak at 5 to 15 years and another at 45 to 60 years. Polymyositis rarely occurs in the pediatric age group, and the mean age is between 50 and 60 years. […] The overall female-to-male incidence ratio is 2 to 3:1. In the United States, the Black race to White race ratio of incidence is 3 to 4:1. […] In Europe, the prevalence significantly increases from the north to the south, and this may be due to either environmental or genetic reasons.

• #16

  https://step2.medbullets.com/rheumatology/120722/dermatomyositis–polymyositis

  female male […] typically in adults 30-50 years of age […] if in children, considered juvenile dermatomyositis […] Risk factors include drugs and physical exertion.

• #17

  https://step1.medbullets.com/msk/112043/polymyositis–dermatomyositis

  Epidemiology […] incidence […] rare […] demographics […] female male […] typically in adults 30-50 years of age […] if in children, considered juvenile dermatomyositis […] risk factors […] drugs […] physical exertion […] […] […] polymyositis an autoimmune myopathy characterized by […] symmetric proximal muscle weakness and no rash

• #18 Polymyositis | Johns Hopkins Myositis Center

  https://www.hopkinsmyositis.org/myositis/polymyositis/

  The incidence of polymyositis increases with age, with the highest rates being seen in the 35-44 and 55-64 year old age groups. Women are two times more likely to suffer from polymyositis than men. […] Polymyositis is an autoimmune disease that causes inflammation in the muscles.

• #19 Myositis: Muscle Inflammation | Inflammatory Myopathy | HSS

  https://www.hss.edu/condition-list_myositis.asp

  Idiopathic inflammatory myopathies (IIM), commonly referred to as myositis, are chronic diseases marked by muscle inflammation. The exact number of people affected by myositis is unknown, but estimates show about 50,000 in the US living with the disease. […] It is estimated that approximately 7,000 people are diagnosed with myositis every year, and there are upwards of 50,000 people in the United States who have it. There is no special geographic area where myositis is more common. […] A peak incidence of idiopathic inflammatory myopathies takes place in people between the ages of 45 and 64 (about 8 to 10 new cases per 100,000 people per year). People in younger (25 to 44) or older (65+) age groups get myositis less often (about 3 to 5 new cases per 100,000 people per year). […] Polymyositis and dermatomyositis affect women two to three times more than men, while inclusion body myositis affects men about one-and-a-half to two times more than women. […] People of predominantly Sub-Saharan African descent are three times more likely to get myositis than people with little or no such ancestry.

• #20 Polymyositis | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/27417

  Autoimmune disorders are the leading cause of increased mortality among the middle-aged population in the United States, with varying incidence rates. Polymyositis rarely presents in childhood and usually affects people 20 and older. Dermatomyositis, however, has a bimodal age distribution affecting the population between 5 to 15 years and 45 to 60 years. The chances of disease development are almost double in women than in men, which is exactly the opposite of IBM. In the United States population, the rate of development of this autoimmune disorder is about 0.5 to 8.4 cases per 100,000 individuals. Having ethnic variation, it has been more commonly reported in Black populations than in White.

• #21 Polymyositis and dermatomyositis epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Polymyositis_and_dermatomyositis_epidemiology_and_demographics

  The 5-year survival rate for polymyositis is 75% and for dermatomyositis is 63%. […] The median survival for polymyositis is 11.0 years and that for dermatomyositis is 12.3 years. […] Dermatomyositis has a bimodal pattern, commonly affects both children and adults over 50 years old. […] Polymyositis commonly affects adults after second decades of their lives and it is rare among children. […] There is no racial predilection to polymyositis and dermatomyositis. […] The female to male ratio is approximately 2 to 1. […] Prevalence of polymyositis and dermatomyositis are lower in young rural men and higher in older urban women.

• #22 Polymyositis: Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/335925-overview

  Idiopathic inflammatory myopathies are relatively rare diseases, with an incidence in the United States that ranges from 0.5-8.4 cases per million population. Polymyositis is more common in the United States within the Black population, with the estimated Black-to-White incidences for polymyositis and dermatomyositis being 5:1 and 3:1, respectively. Internationally, polymyositis is less common among the Japanese. […] Polymyositis and dermatomyositis are more common in women than in men (2:1 ratio), while inclusion body myositis is twice as common in men. […] Polymyositis usually affects adults older than 20 years, especially those aged 45-60 years. Polymyositis rarely affects children. The age of onset of polymyositis with another collagen vascular disease is related to the associated condition. […] Five-year survival rates in polymyositis have been estimated at more than 80%. Mortality is most often related to associated malignancy or pulmonary complications; elderly patients with cardiac involvement or dysphagia also have a higher mortality rate.

• #23 Polymyositis | Johns Hopkins Myositis Center

  https://www.hopkinsmyositis.org/myositis/polymyositis/

  The incidence of polymyositis increases with age, with the highest rates being seen in the 35-44 and 55-64 year old age groups. Women are two times more likely to suffer from polymyositis than men. […] Polymyositis is an autoimmune disease that causes inflammation in the muscles.

• #24 Polymyositis | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/27417

  Autoimmune disorders are the leading cause of increased mortality among the middle-aged population in the United States, with varying incidence rates. Polymyositis rarely presents in childhood and usually affects people 20 and older. Dermatomyositis, however, has a bimodal age distribution affecting the population between 5 to 15 years and 45 to 60 years. The chances of disease development are almost double in women than in men, which is exactly the opposite of IBM. In the United States population, the rate of development of this autoimmune disorder is about 0.5 to 8.4 cases per 100,000 individuals. Having ethnic variation, it has been more commonly reported in Black populations than in White.

• #25 Polymyositis | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/27417

  Autoimmune disorders are the leading cause of increased mortality among the middle-aged population in the United States, with varying incidence rates. Polymyositis rarely presents in childhood and usually affects people 20 and older. Dermatomyositis, however, has a bimodal age distribution affecting the population between 5 to 15 years and 45 to 60 years. The chances of disease development are almost double in women than in men, which is exactly the opposite of IBM. In the United States population, the rate of development of this autoimmune disorder is about 0.5 to 8.4 cases per 100,000 individuals. Having ethnic variation, it has been more commonly reported in Black populations than in White.

• #26 Polymyositis: Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/335925-overview

  Idiopathic inflammatory myopathies are relatively rare diseases, with an incidence in the United States that ranges from 0.5-8.4 cases per million population. Polymyositis is more common in the United States within the Black population, with the estimated Black-to-White incidences for polymyositis and dermatomyositis being 5:1 and 3:1, respectively. Internationally, polymyositis is less common among the Japanese. […] Polymyositis and dermatomyositis are more common in women than in men (2:1 ratio), while inclusion body myositis is twice as common in men. […] Polymyositis usually affects adults older than 20 years, especially those aged 45-60 years. Polymyositis rarely affects children. The age of onset of polymyositis with another collagen vascular disease is related to the associated condition. […] Five-year survival rates in polymyositis have been estimated at more than 80%. Mortality is most often related to associated malignancy or pulmonary complications; elderly patients with cardiac involvement or dysphagia also have a higher mortality rate.

• #27 Incidence and prevalence of idiopathic inflammatory myopathies in Thailand from the Ministry of Public Health data analysis | Scientific Reports

  https://www.nature.com/articles/s41598-024-71633-7

  The epidemiology of idiopathic inflammatory myopathies (IIMs) varies by country. […] We aimed to assess the prevalence and incidence of IIM in the Thai population between 2017 and 2020. […] In 2017, the IIM cases numbered 9,074 among 65,204,797 Thais, resulting in a prevalence of 13.9 per 100,000 population (95% CI 13.6-14.2). […] IIMs were slightly more prevalent among women than men (16.8 vs 10.9 per 100,000). […] Between 2018 and 2020, the incidence of IIMs slightly declined from 5.09 (95% CI 4.9-5.27) in 2017 and 4.92 (95% CI 4.76-5.10) in 2019 to 4.43 (95% CI 4.27-4.60) per 100,000 person-years in 2020. […] The peak age group was 50-69 years. […] Between 2018 and 2020, the majority of cases occurred in southern Thailand, with incidence rates of 7.60, 8.34, and 8.74 per 100,000 person-years.

• #28 Polymyositis | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/27417

  Autoimmune disorders are the leading cause of increased mortality among the middle-aged population in the United States, with varying incidence rates. Polymyositis rarely presents in childhood and usually affects people 20 and older. Dermatomyositis, however, has a bimodal age distribution affecting the population between 5 to 15 years and 45 to 60 years. The chances of disease development are almost double in women than in men, which is exactly the opposite of IBM. In the United States population, the rate of development of this autoimmune disorder is about 0.5 to 8.4 cases per 100,000 individuals. Having ethnic variation, it has been more commonly reported in Black populations than in White.

• #29 Polymyositis: Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/335925-overview

  Idiopathic inflammatory myopathies are relatively rare diseases, with an incidence in the United States that ranges from 0.5-8.4 cases per million population. Polymyositis is more common in the United States within the Black population, with the estimated Black-to-White incidences for polymyositis and dermatomyositis being 5:1 and 3:1, respectively. Internationally, polymyositis is less common among the Japanese. […] Polymyositis and dermatomyositis are more common in women than in men (2:1 ratio), while inclusion body myositis is twice as common in men. […] Polymyositis usually affects adults older than 20 years, especially those aged 45-60 years. Polymyositis rarely affects children. The age of onset of polymyositis with another collagen vascular disease is related to the associated condition. […] Five-year survival rates in polymyositis have been estimated at more than 80%. Mortality is most often related to associated malignancy or pulmonary complications; elderly patients with cardiac involvement or dysphagia also have a higher mortality rate.

• #30 Polymyositis: Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/335925-overview

  Idiopathic inflammatory myopathies are relatively rare diseases, with an incidence in the United States that ranges from 0.5-8.4 cases per million population. Polymyositis is more common in the United States within the Black population, with the estimated Black-to-White incidences for polymyositis and dermatomyositis being 5:1 and 3:1, respectively. Internationally, polymyositis is less common among the Japanese. […] Polymyositis and dermatomyositis are more common in women than in men (2:1 ratio), while inclusion body myositis is twice as common in men. […] Polymyositis usually affects adults older than 20 years, especially those aged 45-60 years. Polymyositis rarely affects children. The age of onset of polymyositis with another collagen vascular disease is related to the associated condition. […] Five-year survival rates in polymyositis have been estimated at more than 80%. Mortality is most often related to associated malignancy or pulmonary complications; elderly patients with cardiac involvement or dysphagia also have a higher mortality rate.

• #31 Myositis: Muscle Inflammation | Inflammatory Myopathy | HSS

  https://www.hss.edu/condition-list_myositis.asp

  Idiopathic inflammatory myopathies (IIM), commonly referred to as myositis, are chronic diseases marked by muscle inflammation. The exact number of people affected by myositis is unknown, but estimates show about 50,000 in the US living with the disease. […] It is estimated that approximately 7,000 people are diagnosed with myositis every year, and there are upwards of 50,000 people in the United States who have it. There is no special geographic area where myositis is more common. […] A peak incidence of idiopathic inflammatory myopathies takes place in people between the ages of 45 and 64 (about 8 to 10 new cases per 100,000 people per year). People in younger (25 to 44) or older (65+) age groups get myositis less often (about 3 to 5 new cases per 100,000 people per year). […] Polymyositis and dermatomyositis affect women two to three times more than men, while inclusion body myositis affects men about one-and-a-half to two times more than women. […] People of predominantly Sub-Saharan African descent are three times more likely to get myositis than people with little or no such ancestry.

• #32 Autoimmune Myopathies – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK532860/

  The estimated prevalence of polymyositis and dermatomyositis (PM/DM) is 5 to 22 per 100,000 persons, and the incidence is approximately 1.2 to 19 per million persons at risk per year. […] The incidence of myositis is increasing over time due to an increase in the detection rate. […] Dermatomyositis is bimodal in age distribution, with one peak at 5 to 15 years and another at 45 to 60 years. Polymyositis rarely occurs in the pediatric age group, and the mean age is between 50 and 60 years. […] The overall female-to-male incidence ratio is 2 to 3:1. In the United States, the Black race to White race ratio of incidence is 3 to 4:1. […] In Europe, the prevalence significantly increases from the north to the south, and this may be due to either environmental or genetic reasons.

• #33 Autoimmune Myopathies – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK532860/

  The estimated prevalence of polymyositis and dermatomyositis (PM/DM) is 5 to 22 per 100,000 persons, and the incidence is approximately 1.2 to 19 per million persons at risk per year. […] The incidence of myositis is increasing over time due to an increase in the detection rate. […] Dermatomyositis is bimodal in age distribution, with one peak at 5 to 15 years and another at 45 to 60 years. Polymyositis rarely occurs in the pediatric age group, and the mean age is between 50 and 60 years. […] The overall female-to-male incidence ratio is 2 to 3:1. In the United States, the Black race to White race ratio of incidence is 3 to 4:1. […] In Europe, the prevalence significantly increases from the north to the south, and this may be due to either environmental or genetic reasons.

• #34 Incidence and prevalence of idiopathic inflammatory myopathies in Thailand from the Ministry of Public Health data analysis | Scientific Reports

  https://www.nature.com/articles/s41598-024-71633-7

  The epidemiology of idiopathic inflammatory myopathies (IIMs) varies by country. […] We aimed to assess the prevalence and incidence of IIM in the Thai population between 2017 and 2020. […] In 2017, the IIM cases numbered 9,074 among 65,204,797 Thais, resulting in a prevalence of 13.9 per 100,000 population (95% CI 13.6-14.2). […] IIMs were slightly more prevalent among women than men (16.8 vs 10.9 per 100,000). […] Between 2018 and 2020, the incidence of IIMs slightly declined from 5.09 (95% CI 4.9-5.27) in 2017 and 4.92 (95% CI 4.76-5.10) in 2019 to 4.43 (95% CI 4.27-4.60) per 100,000 person-years in 2020. […] The peak age group was 50-69 years. […] Between 2018 and 2020, the majority of cases occurred in southern Thailand, with incidence rates of 7.60, 8.34, and 8.74 per 100,000 person-years.

• #35 Incidence and prevalence of idiopathic inflammatory myopathies in Thailand from the Ministry of Public Health data analysis | Scientific Reports

  https://www.nature.com/articles/s41598-024-71633-7

  The incidence of IIMs decreased between 2019 and 2020, most likely due to the COVID-19 pandemic, which reduced reports and investigations. […] The current study determined that the prevalence of IIMs among Thais was similar to that of the majority of IIMs worldwide, with a rate of 13.93 per 100,000 (95 percent CI 13.6-14.21) in 2017. […] Our study reveals a decline in the incidence of IIMs among Thais from 2017 to 2020, with rates lower than those reported in the United States between 2003 and 2008. […] Female cases predominate among IIMs in Thailand, which is consistent with previous research. […] Our research revealed that the peak prevalence of IIMs occurs between 60 and 69 years. […] The presence of IIMs in Thailand is unusual. It peaks among people aged 60 to 69, especially in southern Thailand. […] Furthermore, the frequency of IIM cases decreased significantly between 2019 and 2020, which was most likely influenced by the COVID-19 pandemic.

• #36 Polymyositis | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/29446?embed_domain=hackmd.io%252525252F%2525252540yipuafecsl2jsu8smr5njq%252525252Fbnjhjgjghjghjgh

  There are several forms of the disease. The most common form affects those in their fourth decade. There is a recognized female predilection (F:M = ~2:1). […] Polymyositis is an increasingly rare diagnosis. With advances in medical science, many patients previously diagnosed with polymyositis are being reclassified as having other inflammatory myopathies, such as immune-mediated necrotizing myopathy, inclusion body myositis, or anti-synthetase syndrome. There is conjecture among experts in the literature as to whether polymyositis still exists as a clinical entity, but if it does, it is likely very rare.

• #37 Polymyositis | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/29446?embed_domain=hackmd.io%252525252F%2525252540yipuafecsl2jsu8smr5njq%252525252Fbnjhjgjghjghjgh

  There are several forms of the disease. The most common form affects those in their fourth decade. There is a recognized female predilection (F:M = ~2:1). […] Polymyositis is an increasingly rare diagnosis. With advances in medical science, many patients previously diagnosed with polymyositis are being reclassified as having other inflammatory myopathies, such as immune-mediated necrotizing myopathy, inclusion body myositis, or anti-synthetase syndrome. There is conjecture among experts in the literature as to whether polymyositis still exists as a clinical entity, but if it does, it is likely very rare.

• #38 Polymyositis – Wikipedia

  https://en.wikipedia.org/wiki/Polymyositis

  Polymyositis affects females at greater frequency than males.[11] […] The discovery of several myositis-specific autoantibodies during the past decades has enabled the description of other discrete subsets of diagnosis, specifically the discovery of Antisynthetase syndrome in reducing the number of diagnoses of polymyositis.[12]

• #39 Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States – ACR Meeting Abstracts

  https://acrabstracts.org/abstract/inpatient-epidemiology-of-dermatomyositis-and-polymyositis-in-the-united-states/

  Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States […] Data on inpatient epidemiology, resource utilization, and healthcare expenditures of IIM are not well described. […] The aim of this study was to explore those characteristics using a large national inpatient database. […] A total of 160,528 admissions of patients with a diagnosis of DM/PM occurred in the study period. […] For the primary outcome, the inpatient prevalence of DM/PM was 41.9 cases per 100,000 discharges. […] The inpatient prevalence of DM/PM was higher than what would be expected from the overall incidence. Hospitalizations of these patients were associated with a significantly higher morbidity and mortality. […] The mean total hospital costs, charges, and LOS for patients admitted with DM/PM were higher than patients without DM/PM.

• #40 Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States – ACR Meeting Abstracts

  https://acrabstracts.org/abstract/inpatient-epidemiology-of-dermatomyositis-and-polymyositis-in-the-united-states/

  Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States […] Data on inpatient epidemiology, resource utilization, and healthcare expenditures of IIM are not well described. […] The aim of this study was to explore those characteristics using a large national inpatient database. […] A total of 160,528 admissions of patients with a diagnosis of DM/PM occurred in the study period. […] For the primary outcome, the inpatient prevalence of DM/PM was 41.9 cases per 100,000 discharges. […] The inpatient prevalence of DM/PM was higher than what would be expected from the overall incidence. Hospitalizations of these patients were associated with a significantly higher morbidity and mortality. […] The mean total hospital costs, charges, and LOS for patients admitted with DM/PM were higher than patients without DM/PM.

• #41 Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States – ACR Meeting Abstracts

  https://acrabstracts.org/abstract/inpatient-epidemiology-of-dermatomyositis-and-polymyositis-in-the-united-states/

  Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States […] Data on inpatient epidemiology, resource utilization, and healthcare expenditures of IIM are not well described. […] The aim of this study was to explore those characteristics using a large national inpatient database. […] A total of 160,528 admissions of patients with a diagnosis of DM/PM occurred in the study period. […] For the primary outcome, the inpatient prevalence of DM/PM was 41.9 cases per 100,000 discharges. […] The inpatient prevalence of DM/PM was higher than what would be expected from the overall incidence. Hospitalizations of these patients were associated with a significantly higher morbidity and mortality. […] The mean total hospital costs, charges, and LOS for patients admitted with DM/PM were higher than patients without DM/PM.

• #42 Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States – ACR Meeting Abstracts

  https://acrabstracts.org/abstract/inpatient-epidemiology-of-dermatomyositis-and-polymyositis-in-the-united-states/

  Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States […] Data on inpatient epidemiology, resource utilization, and healthcare expenditures of IIM are not well described. […] The aim of this study was to explore those characteristics using a large national inpatient database. […] A total of 160,528 admissions of patients with a diagnosis of DM/PM occurred in the study period. […] For the primary outcome, the inpatient prevalence of DM/PM was 41.9 cases per 100,000 discharges. […] The inpatient prevalence of DM/PM was higher than what would be expected from the overall incidence. Hospitalizations of these patients were associated with a significantly higher morbidity and mortality. […] The mean total hospital costs, charges, and LOS for patients admitted with DM/PM were higher than patients without DM/PM.

• #43 Polymyositis: Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/335925-overview

  Idiopathic inflammatory myopathies are relatively rare diseases, with an incidence in the United States that ranges from 0.5-8.4 cases per million population. Polymyositis is more common in the United States within the Black population, with the estimated Black-to-White incidences for polymyositis and dermatomyositis being 5:1 and 3:1, respectively. Internationally, polymyositis is less common among the Japanese. […] Polymyositis and dermatomyositis are more common in women than in men (2:1 ratio), while inclusion body myositis is twice as common in men. […] Polymyositis usually affects adults older than 20 years, especially those aged 45-60 years. Polymyositis rarely affects children. The age of onset of polymyositis with another collagen vascular disease is related to the associated condition. […] Five-year survival rates in polymyositis have been estimated at more than 80%. Mortality is most often related to associated malignancy or pulmonary complications; elderly patients with cardiac involvement or dysphagia also have a higher mortality rate.

• #44 Polymyositis and dermatomyositis epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Polymyositis_and_dermatomyositis_epidemiology_and_demographics

  The 5-year survival rate for polymyositis is 75% and for dermatomyositis is 63%. […] The median survival for polymyositis is 11.0 years and that for dermatomyositis is 12.3 years. […] Dermatomyositis has a bimodal pattern, commonly affects both children and adults over 50 years old. […] Polymyositis commonly affects adults after second decades of their lives and it is rare among children. […] There is no racial predilection to polymyositis and dermatomyositis. […] The female to male ratio is approximately 2 to 1. […] Prevalence of polymyositis and dermatomyositis are lower in young rural men and higher in older urban women.

• #45 Polymyositis and dermatomyositis epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Polymyositis_and_dermatomyositis_epidemiology_and_demographics

  The 5-year survival rate for polymyositis is 75% and for dermatomyositis is 63%. […] The median survival for polymyositis is 11.0 years and that for dermatomyositis is 12.3 years. […] Dermatomyositis has a bimodal pattern, commonly affects both children and adults over 50 years old. […] Polymyositis commonly affects adults after second decades of their lives and it is rare among children. […] There is no racial predilection to polymyositis and dermatomyositis. […] The female to male ratio is approximately 2 to 1. […] Prevalence of polymyositis and dermatomyositis are lower in young rural men and higher in older urban women.

• #46 Polymyositis: Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/335925-overview

  Idiopathic inflammatory myopathies are relatively rare diseases, with an incidence in the United States that ranges from 0.5-8.4 cases per million population. Polymyositis is more common in the United States within the Black population, with the estimated Black-to-White incidences for polymyositis and dermatomyositis being 5:1 and 3:1, respectively. Internationally, polymyositis is less common among the Japanese. […] Polymyositis and dermatomyositis are more common in women than in men (2:1 ratio), while inclusion body myositis is twice as common in men. […] Polymyositis usually affects adults older than 20 years, especially those aged 45-60 years. Polymyositis rarely affects children. The age of onset of polymyositis with another collagen vascular disease is related to the associated condition. […] Five-year survival rates in polymyositis have been estimated at more than 80%. Mortality is most often related to associated malignancy or pulmonary complications; elderly patients with cardiac involvement or dysphagia also have a higher mortality rate.

• #47 Polymyositis – adult: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/000428.htm

  Polymyositis can affect people at any age. It is most common in adults between ages 50 and 60, and in older children. It affects women twice as often as men. It is more common in African Americans than white people. […] Response to treatment varies, based on the complications. As many as 1 in 5 people may die within 5 years of developing the condition. […] The major causes of death are cancer and lung disease.

• #48 Polymyositis: Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/335925-overview

  Idiopathic inflammatory myopathies are relatively rare diseases, with an incidence in the United States that ranges from 0.5-8.4 cases per million population. Polymyositis is more common in the United States within the Black population, with the estimated Black-to-White incidences for polymyositis and dermatomyositis being 5:1 and 3:1, respectively. Internationally, polymyositis is less common among the Japanese. […] Polymyositis and dermatomyositis are more common in women than in men (2:1 ratio), while inclusion body myositis is twice as common in men. […] Polymyositis usually affects adults older than 20 years, especially those aged 45-60 years. Polymyositis rarely affects children. The age of onset of polymyositis with another collagen vascular disease is related to the associated condition. […] Five-year survival rates in polymyositis have been estimated at more than 80%. Mortality is most often related to associated malignancy or pulmonary complications; elderly patients with cardiac involvement or dysphagia also have a higher mortality rate.

• #49 Polymyositis – adult: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/000428.htm

  Polymyositis can affect people at any age. It is most common in adults between ages 50 and 60, and in older children. It affects women twice as often as men. It is more common in African Americans than white people. […] Response to treatment varies, based on the complications. As many as 1 in 5 people may die within 5 years of developing the condition. […] The major causes of death are cancer and lung disease.

• #50 Polymyositis – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/polymyositis/symptoms-causes/syc-20353208

  Polymyositis most commonly affects adults in their 30s, 40s or 50s. Women are affected more often than men. […] Your risk of polymyositis is higher if you have lupus, rheumatoid arthritis, scleroderma, or Sjogren’s syndrome. […] People who have polymyositis have an elevated risk of cancer.

• #51 Polymyositis – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/polymyositis/symptoms-causes/syc-20353208

  Polymyositis most commonly affects adults in their 30s, 40s or 50s. Women are affected more often than men. […] Your risk of polymyositis is higher if you have lupus, rheumatoid arthritis, scleroderma, or Sjogren’s syndrome. […] People who have polymyositis have an elevated risk of cancer.

• #52 Polymyositis – adult Information | Mount Sinai – New York

  https://www.mountsinai.org/health-library/diseases-conditions/polymyositis-adult

  Polymyositis can affect people at any age. It is most common in adults between ages 50 and 60, and in older children. It affects women twice as often as men. It is more common in African Americans than white people. […] People with this condition also must be watched carefully for signs of cancer.

• #53 Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: a retrospective cohort study in Japan | Scientific Reports

  https://www.nature.com/articles/s41598-023-44092-9

  Dermatomyositis and polymyositis are rare, idiopathic inflammatory myopathies. Interstitial lung disease is one of the most common and potentially severe extra-muscular manifestations of dermatomyositis and polymyositis and is strongly linked to poor prognosis and early mortality. We aimed to characterise the demographic and clinical characteristics, incidence, and treatment of interstitial lung disease in patients with dermatomyositis or polymyositis. […] The incidence rate of interstitial lung disease per 100 person-years was 18.42 (95% CI 16.4220.59) for dermatomyositis and 5.39 (95% CI 4.436.50) for polymyositis. […] In conclusion, the risk of developing interstitial lung disease was significantly higher in patients with dermatomyositis than with polymyositis, and risk factors were different in the 2 patient groups.

• #54 Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: a retrospective cohort study in Japan | Scientific Reports

  https://www.nature.com/articles/s41598-023-44092-9

  Dermatomyositis and polymyositis are rare, idiopathic inflammatory myopathies. Interstitial lung disease is one of the most common and potentially severe extra-muscular manifestations of dermatomyositis and polymyositis and is strongly linked to poor prognosis and early mortality. We aimed to characterise the demographic and clinical characteristics, incidence, and treatment of interstitial lung disease in patients with dermatomyositis or polymyositis. […] The incidence rate of interstitial lung disease per 100 person-years was 18.42 (95% CI 16.4220.59) for dermatomyositis and 5.39 (95% CI 4.436.50) for polymyositis. […] In conclusion, the risk of developing interstitial lung disease was significantly higher in patients with dermatomyositis than with polymyositis, and risk factors were different in the 2 patient groups.

• #55 Polymyositis – Market Insight, Epidemiology, and Market Forecast – 2034

  https://www.giiresearch.com/report/del1506049-polymyositis-market-insight-epidemiology-market.html

  DelveInsight’s „Polymyositis – Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. […] The Polymyositis epidemiology division provide insights about historical and current Polymyositis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. […] The disease epidemiology covered in the report provides historical as well as forecasted Polymyositis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

• #56 Polymyositis – Market Insight, Epidemiology, and Market Forecast – 2034

  https://www.giiresearch.com/report/del1506049-polymyositis-market-insight-epidemiology-market.html

  The epidemiology segment also provides the Polymyositis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. […] The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Polymyositis key players involved in developing targeted therapeutics. […] What is the historical Polymyositis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan? […] What would be the forecasted patient pool of Polymyositis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan? […] Out of all 7MM countries, which country would have the highest prevalent population of Polymyositis during the forecast period (2020-2034)?

• #57 :: JKMS :: Journal of Korean Medical Science

  https://jkms.org/DOIx.php?id=10.3346/jkms.2019.34.e55

  Using a nationwide population-based database that included most of the Korean population, we estimated an overall IIM prevalence rate of 2.34.4/100,000 persons and an incidence of 2.95.2 per 1,000,000. We did not observe any trends in incidence over a 10-year period. […] Our calculated prevalence and incidence were lower than those reported in a recent study from Sweden between 2007 and 2011 (prevalence of 14/100,000 and incidence of 11/1,000,000) and a meta-analysis of prevalence (14/100,000 between 1982 and 2010 and incidence 7.98/1,000,000 between 1951 and 2010). […] In conclusion, our study observed a slightly lower prevalence and incidence of IIM in Korea compared to recent reports from other countries. More than two-thirds of patients had more than two comorbidities.

• #58 Orphanet: Polymyositis

  https://www.orpha.net/en/disease/detail/732

  A rare idiopathic inflammatory myopathy (IIM) historically characterized by symmetric proximal muscle weakness, elevated muscle enzymes (creatine kinase), myopathic findings on electromyography, and muscle biopsy showing endomyial infiltration composed mainly of macrophages and lymphocytes. […] Prevalence: 1-9 / 100 000. […] Age of onset: Adult, Elderly. […] Research activities on this disease. […] Registry(ies) (35).

• #59 Incidence and prevalence of idiopathic inflammatory myopathies in Thailand from the Ministry of Public Health data analysis | Scientific Reports

  https://www.nature.com/articles/s41598-024-71633-7

  The incidence of IIMs decreased between 2019 and 2020, most likely due to the COVID-19 pandemic, which reduced reports and investigations. […] The current study determined that the prevalence of IIMs among Thais was similar to that of the majority of IIMs worldwide, with a rate of 13.93 per 100,000 (95 percent CI 13.6-14.21) in 2017. […] Our study reveals a decline in the incidence of IIMs among Thais from 2017 to 2020, with rates lower than those reported in the United States between 2003 and 2008. […] Female cases predominate among IIMs in Thailand, which is consistent with previous research. […] Our research revealed that the peak prevalence of IIMs occurs between 60 and 69 years. […] The presence of IIMs in Thailand is unusual. It peaks among people aged 60 to 69, especially in southern Thailand. […] Furthermore, the frequency of IIM cases decreased significantly between 2019 and 2020, which was most likely influenced by the COVID-19 pandemic.

• #60 Autoimmune Myopathies – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK532860/

  The estimated prevalence of polymyositis and dermatomyositis (PM/DM) is 5 to 22 per 100,000 persons, and the incidence is approximately 1.2 to 19 per million persons at risk per year. […] The incidence of myositis is increasing over time due to an increase in the detection rate. […] Dermatomyositis is bimodal in age distribution, with one peak at 5 to 15 years and another at 45 to 60 years. Polymyositis rarely occurs in the pediatric age group, and the mean age is between 50 and 60 years. […] The overall female-to-male incidence ratio is 2 to 3:1. In the United States, the Black race to White race ratio of incidence is 3 to 4:1. […] In Europe, the prevalence significantly increases from the north to the south, and this may be due to either environmental or genetic reasons.

• #61 Polymyositis: What It Is, Causes, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/12053-polymyositis

  Polymyositis is rare. Experts estimate that it affects fewer than 25 out of every 100,000 people every year. […] Polymyositis is an autoimmune disease, but experts aren’t sure what causes it. Autoimmune diseases happen when your immune system accidentally attacks your body instead of protecting it. […] Anyone can develop polymyositis, but some groups of people are more likely to, including: Females. They’re twice as likely to have polymyositis compared to males. […] Because experts aren’t sure what causes it, there’s no way to prevent it. We can’t predict who will develop it or when episodes of symptoms will happen or come back. […] People usually live with polymyositis for the rest of their lives. There’s no cure for it, but most people find a combination of treatments that helps them put polymyositis into remission. […] Some cases of polymyositis cause life-threatening complications. It can be fatal if polymyositis severely affects or damages the muscles in your throat and chest that help you breathe and swallow.

• #62 Polymyositis | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/29446?embed_domain=hackmd.io%252525252F%2525252540yipuafecsl2jsu8smr5njq%252525252Fbnjhjgjghjghjgh

  There are several forms of the disease. The most common form affects those in their fourth decade. There is a recognized female predilection (F:M = ~2:1). […] Polymyositis is an increasingly rare diagnosis. With advances in medical science, many patients previously diagnosed with polymyositis are being reclassified as having other inflammatory myopathies, such as immune-mediated necrotizing myopathy, inclusion body myositis, or anti-synthetase syndrome. There is conjecture among experts in the literature as to whether polymyositis still exists as a clinical entity, but if it does, it is likely very rare.

• #63 Myositis – Polymyositis and Dermatomyositis – Patient.info

  https://patient.info/doctor/myositis-polymyositis-and-dermatomyositis

  Few epidemiological studies have been published. […] One US study showed the incidence and prevalence of dermatomyositis to be 1.4 and 5.8 cases per 100,000 people respectively, with female preponderance and a higher prevalence among older age groups. […] For polymyositis, the incidence was 3.8 and the prevalence 9.7 per 100,000 people. However, polymyositis may have been over-diagnosed because not all studies were based on diagnostic muscle biopsies.

• #64 Myositis – Polymyositis and Dermatomyositis – Patient.info

  https://patient.info/doctor/myositis-polymyositis-and-dermatomyositis

  Few epidemiological studies have been published. […] One US study showed the incidence and prevalence of dermatomyositis to be 1.4 and 5.8 cases per 100,000 people respectively, with female preponderance and a higher prevalence among older age groups. […] For polymyositis, the incidence was 3.8 and the prevalence 9.7 per 100,000 people. However, polymyositis may have been over-diagnosed because not all studies were based on diagnostic muscle biopsies.

• #65 Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States – ACR Meeting Abstracts

  https://acrabstracts.org/abstract/inpatient-epidemiology-of-dermatomyositis-and-polymyositis-in-the-united-states/

  Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States […] Data on inpatient epidemiology, resource utilization, and healthcare expenditures of IIM are not well described. […] The aim of this study was to explore those characteristics using a large national inpatient database. […] A total of 160,528 admissions of patients with a diagnosis of DM/PM occurred in the study period. […] For the primary outcome, the inpatient prevalence of DM/PM was 41.9 cases per 100,000 discharges. […] The inpatient prevalence of DM/PM was higher than what would be expected from the overall incidence. Hospitalizations of these patients were associated with a significantly higher morbidity and mortality. […] The mean total hospital costs, charges, and LOS for patients admitted with DM/PM were higher than patients without DM/PM.

• #66 Polymyositis – Market Insight, Epidemiology, and Market Forecast – 2034

  https://www.giiresearch.com/report/del1506049-polymyositis-market-insight-epidemiology-market.html

  DelveInsight’s „Polymyositis – Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. […] The Polymyositis epidemiology division provide insights about historical and current Polymyositis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. […] The disease epidemiology covered in the report provides historical as well as forecasted Polymyositis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

• #67 Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: a retrospective cohort study in Japan | Scientific Reports

  https://www.nature.com/articles/s41598-023-44092-9

  A meta-analysis of worldwide data published in 2020 found that the global prevalence of ILD in patients with DM or PM was 41%, but was higher in Asia (50%), and lowest in Europe (26%). […] In Japan, the annual incidence rate of DM or PM from 2004 to 2010 was estimated to be 1 to 1.3 per 100,000 person-years and the incidence rate of ILD in these patients is not known. […] We observed an incidence rate of ILD of 18.42 (95% CI 16.4220.59) per 100 person-years in patients with DM, and 5.39 (95% CI 4.436.5) per 100 person-years in patients with PM. […] The incidence rate of ILD was higher in women than in men in PM, and more than twofold higher in patients with DM than with PM.

• #68 Evidence For Immunotherapy In Polymyositis and Dermatomyositis: A Systematic Review – ACR Meeting Abstracts

  https://acrabstracts.org/abstract/evidence-for-immunotherapy-in-polymyositis-and-dermatomyositis-a-systematic-review/

  Dermatomyositis (DM) and polymyositis (PM) are rare chronic inflammatory disorders of muscle. The morbidity and mortality associated with these conditions remains significant despite treatment, which typically begins with high-dose corticosteroids. […] More high quality randomized controlled trials are needed to establish the role of second-line agents, in particular biologics, in the treatment of DM and PM.

• #69 Evidence For Immunotherapy In Polymyositis and Dermatomyositis: A Systematic Review – ACR Meeting Abstracts

  https://acrabstracts.org/abstract/evidence-for-immunotherapy-in-polymyositis-and-dermatomyositis-a-systematic-review/

  Dermatomyositis (DM) and polymyositis (PM) are rare chronic inflammatory disorders of muscle. The morbidity and mortality associated with these conditions remains significant despite treatment, which typically begins with high-dose corticosteroids. […] More high quality randomized controlled trials are needed to establish the role of second-line agents, in particular biologics, in the treatment of DM and PM.

• #70 Incidence and prevalence of idiopathic inflammatory myopathies in Thailand from the Ministry of Public Health data analysis | Scientific Reports

  https://www.nature.com/articles/s41598-024-71633-7

  The incidence of IIMs decreased between 2019 and 2020, most likely due to the COVID-19 pandemic, which reduced reports and investigations. […] The current study determined that the prevalence of IIMs among Thais was similar to that of the majority of IIMs worldwide, with a rate of 13.93 per 100,000 (95 percent CI 13.6-14.21) in 2017. […] Our study reveals a decline in the incidence of IIMs among Thais from 2017 to 2020, with rates lower than those reported in the United States between 2003 and 2008. […] Female cases predominate among IIMs in Thailand, which is consistent with previous research. […] Our research revealed that the peak prevalence of IIMs occurs between 60 and 69 years. […] The presence of IIMs in Thailand is unusual. It peaks among people aged 60 to 69, especially in southern Thailand. […] Furthermore, the frequency of IIM cases decreased significantly between 2019 and 2020, which was most likely influenced by the COVID-19 pandemic.

• #71 Polymyositis – Market Insight, Epidemiology, and Market Forecast – 2034

  https://www.giiresearch.com/report/del1506049-polymyositis-market-insight-epidemiology-market.html

  The epidemiology segment also provides the Polymyositis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. […] The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Polymyositis key players involved in developing targeted therapeutics. […] What is the historical Polymyositis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan? […] What would be the forecasted patient pool of Polymyositis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan? […] Out of all 7MM countries, which country would have the highest prevalent population of Polymyositis during the forecast period (2020-2034)?

• #72 Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States – ACR Meeting Abstracts

  https://acrabstracts.org/abstract/inpatient-epidemiology-of-dermatomyositis-and-polymyositis-in-the-united-states/

  Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States […] Data on inpatient epidemiology, resource utilization, and healthcare expenditures of IIM are not well described. […] The aim of this study was to explore those characteristics using a large national inpatient database. […] A total of 160,528 admissions of patients with a diagnosis of DM/PM occurred in the study period. […] For the primary outcome, the inpatient prevalence of DM/PM was 41.9 cases per 100,000 discharges. […] The inpatient prevalence of DM/PM was higher than what would be expected from the overall incidence. Hospitalizations of these patients were associated with a significantly higher morbidity and mortality. […] The mean total hospital costs, charges, and LOS for patients admitted with DM/PM were higher than patients without DM/PM.

Zobacz więcej